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 1. Introduction 
Impaired cognitive function plays a major role in psychiatric disorders such as 
schizophrenia (SC) (Censits et al., 1997; Heaton et al., 2001). A meta-analysis of 36 
studies that examined abnormal cerebral metabolism in patients with SC found a 
decrease in frontal lobe function that became more pronounced as the duration of the 
disorder increased (Davidson and Heinrichs, 2003; Hill et al., 2004). On the other hand, 
mounting evidence shows that these atypical antipsychotics improve cognitive function 
(Keefe et al., 1999, 2004, 2006; Potkin et al., 2001). 
Several studies have reported that atypical antipsychotics increase dopamine 
release in the prefrontal cortex (Kuroki et al., 1999; Gessa et al., 2000; Ichikawa et al., 
2001; Heidbreder et al., 2001), which may lead to improved cognitive function in 
patients with SC (Kumari. 2015). Although the improvement in cognitive function 
brought by antipsychotics varies with each medication (Wang J 2013), the effects of 
atypical antipsychotics on cerebral function in the frontal lobe remain unknown. 
Near-infrared spectroscopy (NIRS) is a noninvasive and useful method that 
measures only the function of the cerebral cortex, not deep tissue, and has a high 
temporal resolution (0.1 s). Recent reviews have found that activation during a variety 
of frontal lobe tasks is lower in patients with SC than in healthy controls (HCs) (Pu et 
al., 2016, Itakura et al., 2017). 
Therefore, in the present study, to clarify the differential effects of antipsychotics 
 on frontal lobe function, we compared brain function in patients with SC who were 
receiving olanzapine (OLZ), a multi-acting receptor-targeted antipsychotic, or 
risperidone (RIS), a serotonin-dopamine antagonist, with HCs using NIRS. 
 
2. Methods 
2.1. Participants 
The study participants were 20 non-randomized, non-consecutive inpatients and 
outpatients with SC treated with OLZ (n=10) or RIS (n=10), as well as 10 HCs who 
were matched for age (Table 1). SC was diagnosed according to the Diagnostic and 
Statistical Manual of Mental Disorders, 4th edition. All diagnoses were made by two 
experienced psychiatrists, and the comorbidity of mental illness was ruled out for all 
participants. All participants were right-handed (score > 70), according to the Edinburgh 
Handedness Inventory (Oldfield, 1971). The clinical symptoms of SC were evaluated by 
trained psychiatrists using the Positive and Negative Syndrome Scale (PANSS) (Kay et 
al., 1987) on the same day as the NIRS sequences. This study was approved by the 
ethics committee of Fukushima Medical University, and all patients provided their 
consent to participate after having been informed of the methods and purpose of the 
study. 
 
2.2. NIRS measurement and cognitive tasks 
 We used a 52-channel NIRS machine (Hitachi ETG-4000; Hitachi Medical 
Corporation, Tokyo, Japan) (Maki et al., 1995) to measure relative changes in 
oxygenated hemoglobin (oxy-Hb) and deoxygenated hemoglobin (deoxy-Hb) using two 
wavelengths of near-infrared light (695 and 830 nm) in accordance with the modified 
Beer–Lambert law. The NIRS probes were fixed with 3 × 11 shells, with the lowest 
probes positioned along the Fp1–Fp2 line according to the international 10–20 system 
used in Electroencephalogram (Okamoto et al., 2004). This arrangement can measure 
[oxy-Hb] levels from the bilateral prefrontal and superior temporal cortical surface 
regions (Tsuzuki et al., 2007). 
NIRS signals were measured using the methods of Takizawa et al. (2008). The 
cognitive task used was a 60-s verbal fluency task (VFT; letter version). Concentration 
changes in oxy-Hb and deoxy-Hb ([oxy-Hb] and [deoxy-Hb]) were observed during the 
VFT. 
 
2.3. Statistical analysis 
Statistical analysis for between-group comparisons was performed using the 
unpaired t-test. The Mann-Whitney U test was used if normality was not maintained. 
Regarding the NIRS data, mean [oxy-Hb] levels during the task period were calculated, 
and then analysis of variance (ANOVA) was used to compare the three groups. We used 
one-way ANOVA for analysis, with a p level < 0.05 considered to indicate statistical 
 significance. When normality was not maintained, comparisons between the three 
groups were performed using the Kruskal-Wallis method. All statistical analyses were 
performed using IBM SPSS Statistics Version 21 (IBM Inc., Armonk, NY), MATLAB 
R2011 (Math Works Inc., Natick, MA), and Prism 6.0 software (GraphPad Software, 
Inc., San Diego, CA). 
 
3. Results 
The clinical characteristics of the study participants are shown in Table 1. The 
three groups were well matched in terms of gender (χ2=1.875, df=2, p=0.392) and age 
(Kruskal-Wallis χ2 (2, n=30) = 2.586, p=0.274). No significant differences were 
observed in antipsychotic dosages (two-sample t-test, t=1.959, p=0.072), the PANSS 
Total (two-sample t-test, t=0.378, p=0.710) , Positive  (Mann-Whitney U test, U=49, 
p=0.939), Negative (two-sample t-test, t=–0.788, p=0.220)scores, or the task 
performance (one-way ANOVA, F(2,27) = 2.292, p=0.12). The changes in [oxy-Hb] in 
the frontal and temporal region in the three groups are shown in Figure 1A. In the OLZ 
group, the changes in [oxy-Hb] were comparable to those seen in the HC group. The 
changes in [oxy-Hb] were smaller in the RIS group than in the HC group. In the 
prefrontal region (CH46–49), a re-increase in [oxy-Hb] was seen in the RIS group after 
the task was completed; this is a typical and well-known pattern in patients with SC 
(Kinou et al., 2013; Suto et al., 2004; Takizawa et al., 2008, 2014). We then compared 
 the mean [oxy-Hb] levels between three groups in 52 channels. 
Statistically significant differences were observed across the three groups in CH15 
(Kruskal-Wallis χ2 (2, n=26) = 8.089, p=0.018), CH18 (χ2 (2, n=26) = 7.238, p=0.027), 
CH26 (χ2 (2, n=26) = 8.411, p=0.015), CH29 (χ2 (2, n=25) = 7.033, p=0.030), CH35 (χ2 
(2, n=27) = 6.461, p=0.040), CH36 (χ2 (2, n=24) = 6.245, p=0.044), CH37 (χ2 (2, n=22) 
= 10.927, p=0.004), CH39 (χ2 (2, n=30) = 8.712, p=0.013), CH40 (χ2 (2, n=22) = 11.161, 
p=0.004), CH46 (χ2 (2, n=28) = 9.715, p=0.008), CH47 (χ2 (2, n=23) = 13.321, 
p=0.001), CH48 (χ2 (2, n=22) = 11.094, p=0.004), and CH50 (χ2 (2, n=27) = 6.692, 
p=0.035), CH52 (χ2 (2, n=24) = 7.110, p=0.029). Post-hoc testing using Dunn’s test 
showed that the mean [oxy-Hb] levels of OLZ and HC were larger than RIS in CH46 
(p<0.05) (Fig 1(B)). 
In frontal regions (CH25–28, CH36–38, CH46–49), statistically significant 
differences were observed across the three groups (Kruskal-Wallis χ2 (2, n=284) = 
72.500, p<0.001), and the HC group had the largest change in [oxy-Hb]. 
 
4. Discussion 
Notably, the changes in [oxy-Hb] levels in the OLZ group were larger than those 
in the RIS group in the prefrontal region; this suggests that OLZ improves 
hemodynamic patterns and brain function in the prefrontal region more effectively than 
RIS. OLZ ranks better than RIS for overall cognitive score (Désaméricq et al., 2013), 
 and a meta-analysis revealed that OLZ was superior to haloperidol in improving 
negative symptoms and depression, whereas no differences were found between RIS 
and haloperidol (Zhang et al., 2013). Both OLZ and RIS have been found to increase 
dopamine release in the medial prefrontal cortex (Kuroki et al., 1999; Gessa et al., 2000; 
Ichikawa et al., 2001; Heidbreder et al., 2001). On the other hand, OLZ blocks the 
N-methyl–d-aspartate receptor antagonist, ketamine, from inducing an increase in 
[14C]2-deoxyglucose uptake, whereas RIS does not affect this uptake in the medial 
frontal cortex (Duncun et al., 2000). Taken together, OLZ may enhance frontal brain 
function, which can lead to improvements in negative symptoms, depression, and 
cognition in patients with SC. 
In this study, different changes in [oxy-Hb] levels were observed in the RIS and 
OLZ groups, suggesting that NIRS patterns may be affected by antipsychotic drugs. 
Previous studies (Suto et al., 2004; Takizawa et al., 2014) suggest that NIRS is useful 
biomarker for the diagnosis of major psychiatric disorders. On the other hand, Kohmura 
et al. (2013) showed that compared with trazodone and a placebo, mirtazapine increased 
changes in [oxy-Hb] levels. Furthermore, we previously reported a case in which NIRS 
patterns changed after the administration of antipsychotics and lithium (Miura et al., 
2014). Taken together, antipsychotic drugs may have different effects on the frontal 
hemodynamic patterns detected by NIRS, which may be a marker of SC status. 
This study did have several limitations. First, NIRS measurements have 
 insufficient spatial resolution and are limited to the monitoring of only the cortical 
surface (Kameyama et al., 2006). Furthermore, Takahashi et al. (2011) indicated that 
most of the changes in [oxy-Hb] during a VFT measured on the forehead, 
approximately in the frontal pole, would involve skin blood flow. However, we 
calculated mean [oxy-Hb] levels in frontal region during a 60-s VFT that were averaged 
at several channels, which suggests the validity of our results. Second, the participants 
in the present study were outpatients with mild or moderate symptoms who had been 
treated with antipsychotics for a number of years. Since heterogeneity and previous 
treatment effects exist, further longitudinal studies in first-episode patients are needed to 
confirm and expand upon our results. Third, some participants with SC received 
co-medication, and its contents were zotepine, levomepromazine, sodium valproate and 
so on. This might have affected the NIRS results. Finally, the sample size was quite 
small. Given these limitations, it is difficult to reach a definitive conclusion regarding 
the influence of specific drugs. Therefore, our results regarding NIRS should be 
considered preliminary. 
In summary, we found significant differences in NIRS measurements between the 
OLZ and RIS groups, and the changes in [oxy-Hb] levels were larger in the OLZ than in 
the RIS group in the prefrontal region. These results suggest that antipsychotic drugs 
may have different effects on the frontal hemodynamic patterns detected by NIRS, 
which may reflect cerebral function in the frontal region. Because of small sample size 
 and heterogeneity, further studies with a larger sample size and a longitudinal study 
design in patients with first-episode SC are needed to verify our findings. 
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 Figure legend 
Fig. 1. (A) Grand average of waveforms of oxy-Hb changes during verbal fluency task 
in the olanzapine (OLZ) (n = 10) (red line), risperidone (RIS) (n = 10) (blue line), and 
healthy control (HC) groups (n = 10) (green line). (B) Comparison of mean oxy-Hb 
levels between the OLZ (n = 10), RIS (n = 10) and HC groups (n = 10) in CH46 during 
the 60-s verbal fluency task. 
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Table 1 
Characteristics 
OLZ group 
 
RIS group 
 
Control group 
 Pa 
  (n=10)      (n=10)      (n=10)   
Age, years: mean (SD) 26.7 (7.6)   29.7 (8.6)   29.5 (8.5)   0.274 
Gender, men/women: n 6 / 4   3 / 7   5 / 5   0.392 
Education (years) 12.1(1.7)   11.4 (1.3)       0.33 
Illness duration (years) 6.1 (4.6)   8.6 (7.2)   N/A   0.42 
PANSS, mean (SD) 
       
  Total  55.6 (20.7) 
 
52.8 (11.0) 
 
N/A 
 
0.71 
  Positive 14.3 (7.4) 
 
12 (7.2) 
 
N/A 
 
0.94 
  Negative 13.2 (4.7) 
 
15 (5.5) 
 
N/A 
 
0.54 
Antipsychotic dosageb, mg/day: mean (SD) 460 (248)   280 (120)   N/A   0.072 
Task performance, mean (SD) 11.6 (6.9)   11.1 (4.1)   15.8 (4.9)   0.12 
N/A, not applicable 
a. One-way ANOVA was used to test the difference in age and task performance across the three groups. Chi-square test was used to test the difference in 
gender across the three groups. Two sample t-test was used to compare the differences in PANSS Total and CP equivalent. The Mann-Whitney U test was 
used to compare the Education years, Illness duration, PANSS Positive and Negative score. 
b. Antipsychotic dosages are reported as chlorpromazine equivalents calculated based clinically equivalent dosing estimates. 
